These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 38708586)
1. Adult and pediatric relapsing multiple sclerosis phase II and phase III trial design and their primary end points: A systematic review. Hiramatsu K; Maeda H Clin Transl Sci; 2024 May; 17(5):e13794. PubMed ID: 38708586 [TBL] [Abstract][Full Text] [Related]
2. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
3. Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis. Nicholas R; Straube S; Schmidli H; Pfeiffer S; Friede T Mult Scler; 2012 Sep; 18(9):1290-6. PubMed ID: 22422808 [TBL] [Abstract][Full Text] [Related]
4. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M; Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Reich DS; Arnold DL; Vermersch P; Bar-Or A; Fox RJ; Matta A; Turner T; Wallström E; Zhang X; Mareš M; Khabirov FA; Traboulsee A; Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400 [TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate. Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162 [TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
9. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571 [TBL] [Abstract][Full Text] [Related]
10. Teriflunomide for multiple sclerosis. He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study. Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299 [TBL] [Abstract][Full Text] [Related]
12. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Carter NJ; Keating GM Drugs; 2010 Aug; 70(12):1545-77. PubMed ID: 20687620 [TBL] [Abstract][Full Text] [Related]
13. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. Montalban X; Arnold DL; Weber MS; Staikov I; Piasecka-Stryczynska K; Willmer J; Martin EC; Dangond F; Syed S; Wolinsky JS; N Engl J Med; 2019 Jun; 380(25):2406-2417. PubMed ID: 31075187 [TBL] [Abstract][Full Text] [Related]